Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Chinese Patent Office
Harvard Business School
Moodys
US Department of Justice
Citi
Daiichi Sankyo
Federal Trade Commission
US Army

Generated: May 23, 2018

DrugPatentWatch Database Preview

ZANAFLEX Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Zanaflex, and when can generic versions of Zanaflex launch?

Zanaflex is a drug marketed by Covis Pharma Bv and is included in two NDAs.

The generic ingredient in ZANAFLEX is tizanidine hydrochloride. There are eleven drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the tizanidine hydrochloride profile page.
Drug patent expirations by year for ZANAFLEX
Pharmacology for ZANAFLEX
Synonyms for ZANAFLEX
(5-chlorobenzo[2,3-c]1,2,5-thiadiazol-4-yl)-2-imidazolin-2-ylamine, chloride
2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-, monohydrochloride
2,1,3-benzothiadiazol-4-amine,5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-, monohydrochloride
5-(Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine hydrochloride
5-chlor-n-(4,5-dihydro-1h-imidazol-2-yl)-2,1,3-benzothiadiazol-4-aminhydrochlorid
5-chloranyl-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine hydrochloride
5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole hydrochloride
5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole monohydrochloride
5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazolehydrochloride
5-chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiodiazole hydrochloride
5-Chloro-4-[(4,5-dihydro-1H-imidazol-2-yl)amino]-2,1,3-benzothiadiazole Hydrochloride
5-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine hydrochloride
5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine;hydrochloride
5-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazole-4-amine hydrochloride
5-Chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3benzothiadiazole-4-amine hydrochloride
5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)benzo[c][1,2,5]thiadiazol-4-amine hydrochloride
51322-75-9 (Parent)
64461-82-1
A828535
AB-021
AB0015475
AB2000107
AC-22546
AC1L3G42
AC1Q3B8M
AC1Q3BC5
AKOS005267234
AN-021
AN-021A
AN-38752
ARONIS24403
B53E3NMY5C
BB_SC-4087
C9H8ClN5S.HCl
C9H9Cl2N5S
CCG-220602
CCG-222418
CHEBI:9609
CHEMBL1200329
CPD000499584
CS-2091
D00776
DB-051946
DS 103-282
DS-103-282
DS-103282
DS-103282 ch
DTXSID9046990
EN300-49853
FT-0656022
HY-B0194A
I14-2831
KS-0000478D
KS-1120
LP01114
LS-40461
M962
MFCD00798231
MLS001076686
MLS001306412
MLS001333593
MolPort-000-855-983
NC00654
NCGC00261799-01
NE33269
NVD-422
s1437
SAM002548961
SAM002643509
SBB080814
SC-12218
SCHEMBL41199
SMR000499584
Tizanidine (hydrochloride)
Tizanidine Hcl
Tizanidine hydrochloride
Tizanidine hydrochloride (JP17/USAN)
Tizanidine hydrochloride [USAN:JAN]
Tizanidine hydrochloride, >=98% (HPLC), powder
Tizanidine hydrochloride, 500 mug/mL in methanol, certified reference material
Tizanidine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Tizanidine hydrochloride, United States Pharmacopeia (USP) Reference Standard
tizanidine monohydrochloride
Tox21_501114
UNII-B53E3NMY5C
Zanaflex (TN)
Zanaflex;Sirdalud
ZWUKMNZJRDGCTQ-UHFFFAOYSA-N

US Patents and Regulatory Information for ZANAFLEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis Pharma Bv ZANAFLEX tizanidine hydrochloride CAPSULE;ORAL 021447-001 Aug 29, 2002 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Covis Pharma Bv ZANAFLEX tizanidine hydrochloride TABLET;ORAL 020397-002 Feb 4, 2000 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Covis Pharma Bv ZANAFLEX tizanidine hydrochloride CAPSULE;ORAL 021447-002 Aug 29, 2002 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Covis Pharma Bv ZANAFLEX tizanidine hydrochloride CAPSULE;ORAL 021447-003 Aug 29, 2002 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for ZANAFLEX
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Capsules 2 mg, 4 mg and 6 mg ➤ Subscribe 2007-08-10

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Cantor Fitzgerald
Mallinckrodt
Express Scripts
Deloitte
Merck
Fish and Richardson
Argus Health
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.